Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

The SPDR S&P Biotech ETF (XBI), a smart beta fund managed by State Street with over $5.42 billion in assets, tracks the modified equal-weight S&P Biotechnology Select Industry Index and features a competitive 0.35% expense ratio. While providing diversified exposure across 129 holdings in the healthcare sector, including significant allocations to Alnylam Pharmaceuticals, the fund reported a 3.76% YTD return but a -7.66% decline over the last year (as of 09/16/2025). With a 3-year trailing standard deviation of 28.28%, XBI is characterized as a high-risk option within the biotechnology ETF landscape, despite its sub-1.0 beta of 0.89.

Analysis

The SPDR S&P Biotech ETF (XBI) is a significant smart beta fund with over $5.42 billion in assets, offering exposure to the biotechnology sub-industry through a modified equal-weight strategy. This structure distinguishes it from market-cap weighted peers by providing broader exposure across its 129 holdings, with the top ten constituents, including Alnylam Pharmaceuticals (ALNY), accounting for a moderate 27.41% of total assets. The fund's competitive 0.35% annual expense ratio is a key advantage. However, its performance has been mixed, posting a 3.76% year-to-date return while being down 7.66% over the last year, as of September 16, 2025. The fund is characterized as a high-risk investment, underscored by a high three-year trailing standard deviation of 28.28%, although its beta of 0.89 suggests lower volatility relative to the broader market. The wide 52-week trading range of $69.80 to $104.18 further illustrates the sector's inherent price volatility.

Key Decisions for Investors

• Investors with a high-risk tolerance may view the fund's recent one-year underperformance and equal-weighting as a strategic opportunity for non-cap-weighted exposure to a potential rebound in the biotech sector.
• Given the fund's high standard deviation of 28.28%, investors must be prepared for significant price volatility and should consider its role as a satellite holding for targeted sector exposure rather than a core portfolio position.
• It is prudent to compare XBI's structure and performance against alternatives like the market-cap weighted iShares Biotechnology ETF (IBB) to determine which weighting methodology best aligns with an investor's outlook on the industry's large-cap versus small- and mid-cap constituents.
• Monitor the fund's performance relative to its 52-week range ($69.80 - $104.18) to gauge shifts in market sentiment and potential entry or exit points.